The rise of DOLs doesn’t mean pharma should upend KOL approach.
Read Roberts
Advertisement
Director, KOL Data Solutions, PRECISIONscientia
Articles by Read Roberts
Advertisement
Latest Updated Articles
Food for Thought: Make Room for Multiple OpinionsMarch 10th 2023
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
3
Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham
4
Pharmaceutical Executive Daily: FDA Approves Fayuvi
5